PKU is a congenital amino acid metabolic disorder. In one of the following rare variants of PKU Dihydro Biopterin synthesis is affected. The enzyme deficient is
## **Core Concept**
Phenylketonuria (PKU) is a congenital amino acid metabolic disorder characterized by the inability to break down the amino acid phenylalanine (Phe), primarily due to defects in the enzyme phenylalanine hydroxylase (PAH) or its cofactor, tetrahydrobiopterin (BH4). BH4 is crucial for the proper functioning of PAH and other hydroxylases.
## **Why the Correct Answer is Right**
The correct answer involves understanding the role of BH4 in PKU and the specific enzymes involved in its synthesis. Dihydrobiopterin (BH2) is a precursor in the synthesis of BH4. The enzyme responsible for converting BH2 to BH4 is **dihydropteridine reductase (DHPR)** or more accurately in this context, the regeneration of BH4 from BH2 involves **dihydropteridine reductase**. However, a more directly related enzyme to BH4 synthesis and regeneration is **6-pyruvoyl-tetrahydrobiopterin synthase** for the de novo synthesis pathway, but specifically for the recycling and maintaining BH4 levels, **dihydropteridine reductase** plays a crucial role.
## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because while it might relate to an enzyme involved in amino acid metabolism, without specifying, it's hard to directly refute, but it's not the direct answer related to BH4 synthesis or recycling.
- **Option B:** This option is incorrect because it does not directly relate to the known enzymes specifically deficient in the context of BH4 synthesis or recycling defects leading to PKU.
- **Option C:** This option could potentially relate to an aspect of amino acid metabolism but does not directly pertain to the BH4 pathway as specifically as another option does.
- **Option D:** This option, **6-pyruvoyl-tetrahydrobiopterin synthase**, is actually involved in the synthesis of BH4 but a defect here leads to a form of hyperphenylalaninemia or a variant of PKU. However, the question hints at a defect affecting dihydrobiopterin synthesis or utilization.
## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that not all PKU is due to PAH deficiency; about 2% of PKU cases are due to defects in BH4 synthesis or recycling. These defects require different management strategies, including BH4 supplementation.
## **Correct Answer:** .